Adjuvant Cemiplimab Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
Adjuvant therapy with cemiplimab improved DFS vs placebo in patients with high-risk cutaneous squamous cell carcinoma after surgery.
Adjuvant therapy with cemiplimab improved DFS vs placebo in patients with high-risk cutaneous squamous cell carcinoma after surgery.
Full results from the phase 1/2 REZILIENT1 trial evaluating zipalertinib in NSCLC will be shared at a future medical conference.
Adding CRT to chemotherapy did not improve RFS in resected gallbladder cancer in the phase 3 ACCELERATE trial.
Li–Fraumeni syndrome (LFS) essentially guarantees a cancer diagnosis in an affected individual’s lifetime. Findings of this study reveal a difficulty for patients with LFS to…
Advancing insights in metastatic renal cell carcinoma – International Urology Cancer Summit / Alessandro Lazzarini, Alessio Signori, cancer, International
This comprehensive genomic analysis of 596 patients with endometrial cancer investigated the characteristics of DNA polymerase epsilon (POLE) mutations. The results revealed no significant genomic…
The European Commission has approved blinatumomab as consolidation therapy for Ph-negative, CD19-postive B-cell precursor acute lymphoblastic leukemia.
Listen to medical professionals and experts talk about hot topics in ASTRO’s new Social Education Series on Diversity, Equity and Inclusion in Radiation Oncology.
An abstract is unavailable.
FreeWill lets you make your last will and testament quick, easy, and completely free. It is a simple online legal will maker that helps you…
NOMINATE The Giants of Cancer Care ® program, presented by OncLive ®, recognizes and celebrates the individuals who have achieved landmark successes within the global…